Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroid‐refractory/dependent acute, gastrointestinal graft‐versus‐host disease: A case series

Saved in:
Bibliographic Details
Published inAmerican journal of hematology Vol. 96; no. 12; pp. E461 - E463
Main Authors Biliński, Jarosław, Jasiński, Marcin, Tomaszewska, Agnieszka, Lis, Karol, Kacprzyk, Piotr, Chmielewska, Lidia, Karakulska‐Prystupiuk, Ewa, Mullish, Benjamin H., Basak, Grzegorz W.
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.12.2021
Wiley Subscription Services, Inc
Subjects
Acute Disease
Aged
Fecal Microbiota Transplantation
Fecal microflora
Female
Graft vs Host Disease - therapy
Humans
Janus Kinases - antagonists & inhibitors
Male
Microbiota
Middle Aged
Nitriles - therapeutic use
Protein Kinase Inhibitors - therapeutic use
Pyrazoles - therapeutic use
Pyrimidines - therapeutic use
Steroids - therapeutic use
Transplantation
Online AccessGet full text

Cover

More Information
Bibliography:Jarosław Biliński and Marcin Jasiński contributed equally to this work.
Funding information
Imperial College London; NIHR Imperial Biomedical Research Centre (BRC) based at Imperial College Healthcare NHS Trust; NIHR Academic Clinical Lectureship, Grant/Award Number: CL‐2019‐21‐002
ISSN:0361-8609
1096-8652
DOI:10.1002/ajh.26365